Aoki Motokuni, Morishita Ryuichi
Department of Geriatric Medicine, Osaka University Graduate School of Medicine.
Nihon Rinsho. 2006 Apr;64(4):762-8.
The clinical consequences of peripheral arterial disease include pain on walking, pain at rest and loss of tissue integrity in the distal ischemic limbs. Although development of beneficial drugs and intervention devices do contribute to the treatment of this disease, critical limb ischemia is estimated to develop in 500 to 1,000 individuals per million per year. As angiogenic growth factors can stimulate the development of collateral arteries, a concept called "therapeutic angiogenesis" is now evaluated in the clinical fields. Recent progress in molecular biology has led to the development of gene therapy as a new strategy to treat a variety of cardiovascular diseases using angiogenic growth factors such as vascular endothelial growth factor (VEGF). Therapeutic angiogenesis using angiogenic growth factors is expected to be a new treatment for patients with severe ischemic heart or peripheral arterial disease.
外周动脉疾病的临床后果包括行走时疼痛、静息时疼痛以及远端缺血肢体的组织完整性丧失。尽管有益药物和介入装置的研发确实有助于该疾病的治疗，但据估计，每年每百万人群中会有500至1000人发展为严重肢体缺血。由于血管生成生长因子可刺激侧支动脉的形成，目前临床领域正在评估一种名为“治疗性血管生成”的概念。分子生物学的最新进展促使基因治疗的发展，这是一种使用血管内皮生长因子（VEGF）等血管生成生长因子治疗多种心血管疾病的新策略。利用血管生成生长因子进行治疗性血管生成有望成为重症缺血性心脏病或外周动脉疾病患者的一种新治疗方法。
